ClinicalTrials.gg
Not yet recruitingNCT07260058Updated Dec 2, 2025

Immune Cell Therapy for Advanced Solid Tumors

A Phase 1/2 interventional study of Autologous immune Cells and Standard chemotherapy in Lung Cancer (Locally Advanced or Metastatic), Liver Cancer (Locally Advanced or Metastatic) and Colorectal Cancer (Locally Advanced or Metastatic), sponsored by Liaoning Medical Diagnosis and Treatment Technology Research and Development Co., Ltd.. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-02.

Primary conditionnone(registry's first term: Lung Neoplasms)Many cancersIs this wrong?The study is open to many cancers (its listed conditions name solid tumors in general), and its title does not single out Lung Neoplasms, so we do not take that as its main condition. It is not compared with other studies by condition.

Sponsored by Liaoning Medical Diagnosis and Treatment Technology Research and Development Co., Ltd. · Phase 1/2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
48
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

The autologous immune cell induction technology used in this project involves transforming peripheral blood mononuclear cells (PBMC) into autologous DC cells, NK cells, CIK cells and other immune cells through cytokine induction, and then re-administering them to the patients. This therapy utilizes biotechnology to culture the immune cells of cancer patients in vitro and then re-infuse them back into the body, stimulating and enhancing the body's own immune function, killing and inhibiting cancer cells, eliminating small and residual lesions, or achieving the goal of treating cancer by significantly inhibiting the proliferation of residual cancer cells.

Read the detailed description

This project focuses on the DC autologous immunocyte therapy based on the core technology of screening tumor antigen dominant CTL epitope peptides through independent patent technology. It is a cutting-edge research direction in the field of tumor immunotherapy in recent years. The non-engineered DC cells induced by special induction techniques can effectively overcome the shortcomings of the poor therapeutic effect of engineered gene editing technology on solid tumors, and effectively achieve targeted killing of tumors. The DC-CIK immunocyte therapy adopted in this project utilizes the original discovery of HLA-A molecule-restricted tumor-related antigen CTL epitope peptides to modify DC. On the one hand, through subcutaneous injection in vivo, it induces CD8+ T cells to produce CTL with memory function to play a role in eliminating and monitoring the protein with high expression of the tumor antigen source. On the other hand, it induces CD8+ T cells to produce CTL with memory function in vitro, and directly reinfuses CTL to exert the role of eliminating and monitoring the protein with high expression of the tumor antigen source. In the previous experimental studies, the CTL induced by G22 antigen-loaded DC has shown significant "identification" and targeted "killing" capabilities against various solid tumor cell lines and primary tumor cells isolated from tumor tissues. In animal experiments, it also shows the ability to induce the body to produce a strong immune response against various solid tumors such as breast cancer and non-small cell lung cancer, significantly inhibiting tumor growth, prolonging progression-free survival, and showing no obvious toxic side effects, having a promising application prospect. It has high individualization: customized based on the tumor mutation spectrum of patients, avoiding "off-target" damage to normal tissues. It has high safety: clinical studies have shown that the side effects are mild, mainly including injection site reactions or transient fever 37. Combined treatment potential: it can be used in combination with PD-1 inhibitors, chemotherapy or radiotherapy to enhance efficacy.

At present, self-active immune cell therapy based on tumor antigen-specific CTL epitope peptides has achieved significant progress in both research and clinical application in China. Personalized tumor vaccines, targeted immunoregulatory strategies for the tumor microenvironment, and combination treatment strategies are providing new concepts and methods for tumor therapy. In summary, the "Clinical Research on Safety and Effectiveness of Autologous Immune Cell Therapy for Advanced Solid Tumors" is expected to provide a clinical trial basis for the development of safe and effective clinical immunotherapies for patients with solid tumors.

02

Conditions studied

  • Lung Cancer (Locally Advanced or Metastatic)
  • Liver Cancer (Locally Advanced or Metastatic)
  • Colorectal Cancer (Locally Advanced or Metastatic)
  • Breast Cancer (Locally Advanced or Metastatic)
  • Advanced Solid Tumors

Keywords

  • Advanced Solid Tumors
  • Metastatic Lung Cancer
  • Metastatic Liver Cancer
  • Metastatic Colorectal Cancer
  • Metastatic Breast Cancer
  • Autologous Immune Cell Therapy
  • Dendritic Cell Vaccine
  • CIK Cells
  • NK Cells
03

In context

Lead sponsor

Liaoning Medical Diagnosis and Treatment Technology Research and Development Co., Ltd. is the lead sponsor of 2 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

To be eligible to participate in this study, an individual must meet all of the following criteria:

  1. The participant must voluntarily participate in the study and provide written 。
  2. Age ≥ 18 years, male or female.
  3. and/or cytologically confirmed locally advanced or solid tumor: lung cancer, liver cancer, colorectal cancer, or breast cancer.
  4. (Eastern Cooperative Oncology Group) performance status score ≤ 2.
  5. ≥ 3 months.
  6. Has not received any other cellular immunotherapy within 3 months prior to enrollment.
  7. Has at least one according to (Response Evaluation Criteria in Solid Tumors) Version 1.1.
  8. Adequate organ function, defined as follows:

Hematology:

White Blood Cell (WBC) count > 3.5 × 10⁹/L Lymphocyte count > 0.9 × 10⁹/L Monocyte count > 0.16 × 10⁹/L (ANC) > 1.5 × 10⁹/L (PLT) count > 75 × 10⁹/L (HB) > 75 g/L Blood Biochemistry: Total ≤ 1.5 × (Upper Limit of Normal) (ALT) and Aspartate Aminotransferase (AST) ≤ 2.5 × ULN (≤ 5 × ULN if liver metastases are present)

Coagulation:

(PT) and International Normalized Ratio (INR) ≤ 1.5 × ULN

Exclusion criteria

Exclusion Criteria:

An individual who meets any of the following criteria will be excluded from participation in this study:

  1. Prior receipt of any salvage chemotherapy, implanted intraperitoneal chemotherapy, targeted therapy, or biological immunotherapy (except: patients whose disease progressed more than 6 months after completing adjuvant, , or radiosensitizing chemotherapy, or more than 1 month after intraperitoneal chemoperfusion/wash, are eligible, provided chemotherapy-related toxicities have recovered to Grade 1 or below, excluding alopecia).
  2. Major surgical procedure within 4 weeks prior to enrollment, with incomplete recovery from side effects.
  3. History of any active within 5 years, except for the specific cancer under investigation in this trial and cured localized tumors such as carcinoma in situ of the cervix, basal cell carcinoma of the skin, and prostate carcinoma in situ.
  4. Presence of more than a small amount of pericardial effusion, or uncontrolled pleural or peritoneal effusion, defined as: detectable by physical examination at screening, or requiring therapeutic paracentesis during the screening period.
  5. Inability to tolerate peripheral blood collection due to various reasons (e.g., severe coronary heart disease, inability to establish peripheral venous access).
  6. Severe cardiovascular disease, including uncontrolled hypertension, unstable angina, history of myocardial infarction within the past 6 months, congestive heart failure > (New York Heart Association) Class III, or severe arrhythmia.
  7. Active infection, unexplained fever ≥ 38.5°C within 7 days prior to medication, or baseline white blood cell count > 15×10⁹/L; OR any severe acute or chronic infection requiring systemic antibacterial, antifungal, or antiviral therapy at screening (except for active hepatitis).
  8. Any active disease or history of autoimmune diseases (e.g., but not limited to: autoimmune hepatitis, interstitial pneumonia, uveitis, enteritis, hepatitis, hypophysitis, vasculitis, nephritis, hyperthyroidism; Patients with vitiligo; Patients with childhood asthma that has completely resolved in adulthood without any intervention are eligible; Asthma requiring bronchodilator medical intervention is excluded). Patients are eligible if: they have a history of autoimmune-related hypothyroidism and are on stable thyroid hormone replacement therapy; or have type I diabetes controlled by insulin therapy.
  9. History of drug allergy.
  10. Pregnant or lactating women; OR women of or men with pregnant partners who are unwilling to use adequate during the planned trial period (from the screening visit until 120 days after the last study treatment).
  11. History of organ transplantation.
  12. Any other condition that, in the investigator's judgment, would make the participant unsuitable for the study.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
48 participants (estimated)

Study arms

  • Experimental
    Experimental Group

    This arm includes all participants who receive the investigational autologous immune cell therapy (either DC-CIK or NK cells), either alone or in combination with chemotherapy. It consolidates the following original arms: Phase I - DC-CIK Therapy Arm Intervention Name: Autologous DC-CIK Cells Phase I - NK Therapy Arm Intervention Name: Autologous NK Cells Phase II - DC-CIK + Chemotherapy Arm Intervention Name: Autologous DC-CIK Cells+Standard Chemotherapy Phase II - NK + Chemotherapy Arm Intervention Name:Autologous NK Cells+Standard Chemotherapy

    Biological: Autologous immune Cells · Drug: Standard chemotherapy

  • Active comparator
    Control Group

    This arm includes all participants who receive standard chemotherapy alone, without any investigational cell therapy. It consolidates the following original arms: Phase II - Chemotherapy Control Arm (HLA-A Positive) Phase II - Chemotherapy Control Arm (HLA-A Negative)

    Drug: Standard chemotherapy

Interventions

  • BiologicalAutologous immune Cells

    1. Autologous DC-CIK Cells:Dendritic Cells (DC) and Cytokine-Induced Killer (CIK) cells are manufactured ex vivo from the participant's own peripheral blood mononuclear cells (PBMCs). DC cells (\>5x10⁶ cells) are administered via subcutaneous injection. CIK cells (\>5x10⁹ cells) are administered via intravenous infusion. 2. Autologous NK Cells:Natural Killer (NK) cells are manufactured ex vivo from the participant's own peripheral blood mononuclear cells (PBMCs). NK cells (≥3x10⁹ cells) are administered via intravenous infusion.

  • DrugStandard chemotherapy

    Investigator's choice of standard chemotherapy regimen(s) appropriate for the participant's specific type of advanced solid tumor (lung, liver, colorectal, or breast cancer), administered according to local clinical practice.

06

What researchers measure

Primary outcomes

  1. Phase II Primary Outcome: Objective Response Rate (ORR)

    The proportion of participants who achieve a best overall response of complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1.

    Time frame: From randomization until disease progression, assessed up to approximately 24 months

  2. Phase I Primary Outcome: Incidence of Adverse Events (AEs)

    The safety and tolerability of the autologous immune cell therapies (DC-CIK and NK) will be assessed by the incidence, type, and severity of adverse events. All AEs will be graded according to the NCI Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 5.0.

    Time frame: From cell infusion up to 3 months after the last infusion

Secondary outcomes

  1. Progression-Free Survival (PFS)

    The length of time during which a participant remains alive and their disease does not progress.

    Time frame: From the start of treatment (Phase I) or randomization (Phase II) until disease progression or death from any cause, assessed up to approximately 24 months

  2. Overall Survival (OS)

    The length of time from the start of treatment that participants are still alive.

    Time frame: From the start of treatment (Phase I) or randomization (Phase II) until death from any cause, assessed up to approximately 36 months

  3. Disease Control Rate (DCR)

    The proportion of participants who achieve a best overall response of complete response (CR), partial response (PR), or stable disease (SD) according to RECIST 1.1.

    Time frame: From the start of treatment until the end of 4 treatment cycles, assessed up to 4 months

  4. Duration of Response (DoR)

    The length of time that a tumor continues to respond to treatment without the cancer growing or spreading.

    Time frame: From the first documented response (CR or PR) until disease progression or death, assessed up to approximately 24 months

  5. Time to Recurrence (TTR)

    The time from the start of treatment until the first documented recurrence of the cancer.

    Time frame: From the start of treatment until disease recurrence, assessed up to approximately 24 months

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Yes — What IPD? All of the individual participant data collected during the trial, after de-identification. When? Beginning 12 months after the primary publication and ending 36 months thereafter. With Whom? Researchers who provide a methodologically sound proposal. For What? To achieve aims in the approved proposal. Proposals should be directed to [Corresponding Author Email]. To gain access, data requestors will need to sign a data access agreement. Supporting Info? Study Protocol, Statistical Analysis Plan (SAP), Informed Consent Form (ICF)

Supporting information: Study protocol

Time frame: Beginning 12 months after the primary publication and ending 36 months thereafter.

Access criteria: All of the individual participant data collected during the trial, after de-identification.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Dec 2025; primary completion for Jun 2027, 18 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 28, 2025
First posted
Dec 2, 2025
StartEst.
Dec 1, 2025
Primary completionEst.
Jun 30, 2027
CompletionEst.
Dec 31, 2027
Last update
Dec 2, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 2, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07260058
Lead sponsor
Liaoning Medical Diagnosis and Treatment Technology Research and Development Co., Ltd.
Collaborators
Liaoning Cancer Hospital & Institute
Responsible party
Sponsor
First posted
Dec 2, 2025
Start date
Dec 1, 2025 (estimated)
Primary completion
Jun 30, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Dec 2, 2025

Study contacts

Chen Lin, Doctor
Contact
jiaoxue@lnmdtc.com
+86 024-88456888
Wei Minjie, Doctor
study chair · Liaoning Medical Diagnosis and Treatment Technology Research and Development Co., Ltd.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion